PREVALENT aspires to develop, use and provide access to robust pre-clinical pipelines ensuring data quality and reproducibility, which will improve the success rates of drugs reaching the clinical trial phase.
Open calls of participating infrastructures
News & Events
Variability in Genome Editing Outcomes Challenges for Research Reproducibility and Clinical Safety
Researchers at MRC Harwell, alongside their colleagues at Université de Strasbourg and Great Ormond Street Institute of Child Health, have published a review in Molecular Therapy (https://www.sciencedirect.com/science/article/pii/S1525001620301490?via%3Dihub). The review explores the reliability and challenges of genome editing application in both research and in clinic.Show detail
September 17 – 18, 2020 | Prague, Czech Republic
2nd CCP Phenogenomics Conference 2020
The first day will be devoted to the theme “From chemistry via preclinical pipeline to therapeutics“, which emphasizes the translation of the basic research into the application. The second day is specifically devoted to CCP’s users and cooperation partners working in the field of immunology, hematology, genetic base of diseases, and neurobiology.Show detail